Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ... Today in History: May 16, China’s Cultural Revolution begins ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug ... never been approved by the FDA. "Fella even tells patients that its untested oral drug is better than Lilly's approved ...

Hence, it’s imperative that Lilly demonstrate remarkable results on its next-gen product in its obesity drugs portfolio through Orforglipron. The Phase III results for its oral weight loss pill ...

If approved ... view - on weight loss, blood sugar control, tolerability, safety," BofA Securities analysts led by Tim Anderson wrote. BofA reiterated its buy rating on Lilly's stock and its ...

Eli Lilly (NYSE ... although it was approved only in late 2023. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet ...

Eli Lilly, the drugmaker behind the blockbuster weight loss ... available drug. Mochi representatives did not respond to requests for comment. Lilly's complaint against Henry Meds alleges the ...